Gilead Sciences, Inc. 13F Holdings · Q2 2026
Gilead Sciences, Inc. reported 5 securities worth $1.65B in its SEC 13F filing for Q2 2026 (period ended 2026-06-30). Top holdings: RCUS (58.76%), LKFT (30.34%), ASMB (8.30%). Among its top 25 positions this quarter: 1 added, 1 exited.
| Rank | Ticker | Company | Value | % Portfolio | Shares | Action |
|---|---|---|---|---|---|---|
| 1 | RCUS | Arcus Biosciences Inc. | $968.8M | 58.76% | 31.4M | Hold |
| 2 | LKFT | Lakefront Biotherapeutics | $500.2M | 30.34% | 16.7M | Hold |
| 3 | ASMB | Assembly Biosciences Inc. | $136.8M | 8.30% | 5.0M | Added |
| 4 | KYTX | Kyverna Therapeutics Inc. | $36.8M | 2.23% | 4.1M | Hold |
| 5 | XLO | Xilio Therapeutics Inc. | $6.2M | 0.38% | 650,389 | Hold |
| 6 | ACLX | Arcellx Inc | $0 | 0.00% | 0 | Exited |
Source: SEC Form 13F filings · as of 2026-06-30
Every position in this 13F-HR, with its change from the prior quarter.
13F holdings, latest quarter
SourceSEC EDGAR13F-HR